AbbVie Inc.

(New York Stock Exchange)

Top News rankings and signal summaries are processed using AI and may contain errors.

21
Bullish +65

AbbVie stock sits 3.06 percent below its 52-week high

Dividend Earnings report AI-generated analysis

AbbVie Inc. reported second-quarter 2026 revenue of USD 16.99 billion, representing a 10.20 percent year-over-year increase. The company also delivered adjusted earnings per share of USD 3.65, which beat the market consensus estimate of USD 3.61 by four cents. This positive performance provides a solid...

Bullish Signals

  • Revenue grew 10.20% YoY to USD 16.99 billion in Q2 2026.
  • EPS beat consensus by four cents at USD 3.65.
  • Morgan Stanley raised price target to USD 310.00 with overweight rating.
  • Quarterly dividend set at USD 1.73 per share.
22
Bullish +65

AbbVie presents 22 IBD abstracts and AbbVie stock costs EUR 247.55

Acquisition Drug approval Earnings report AI-generated analysis

AbbVie Inc. announced the presentation of 22 abstracts focused on inflammatory bowel disease at the American College of Gastroenterology (ACG) meeting held in October 2026. The company highlighted significant clinical data for its key products, SKYRIZI and RINVOQ, demonstrating strong efficacy in treating fistulizing disease...

Bullish Signals

  • Revenue grew 10.20% to USD 16.99 billion.
  • EPS beat consensus at USD 3.65.
  • RINVOQ achieved 93.30% remission in patients.
  • SKYRIZI Phase 3 AFFIRM results presented.
  • Guggenheim Buy rating with USD 288 target.
23
Somewhat Bullish +45

AbbVie stock cuts its Q3 EPS guidance to USD 3.730-3.770

Guidance lowered AI-generated analysis

AbbVie Inc. has lowered its third-quarter 2026 adjusted earnings per share (EPS) guidance to a range of USD 3.730-3.770, which falls below the market consensus estimate of USD 3.850. The company attributes this downward revision primarily to acquired in-process research and development costs and milestone...

Bullish Signals

  • Revenue grew 10.2% YoY to $16.99B in Q2 2026.
  • Adjusted EPS rose to $3.65 from $2.97 prior year.
  • Bank of America raised target to $289 with Buy rating.
  • Analyst consensus average price target is $278.86.

Bearish Signals

  • Cut Q3 2026 EPS guidance to $3.73-$3.77, below consensus.
  • Lower guidance due to $216M one-time acquired R&D costs.
24
Bullish +65

AbbVie stock heads toward October 30 results after 10.2 percent growth

Dividend Earnings report AI-generated analysis

AbbVie Inc. reported strong second-quarter financial performance with revenue reaching USD 16.99 billion, representing a 10.2% increase year-over-year. Adjusted diluted earnings per share (EPS) surged by 22.9% to USD 3.65, driven by the successful commercialization of newer medicines like Skyrizi and Rinvoq which are effectively...

Bullish Signals

  • Revenue grew 10.2% YoY to $16.99B in Q2.
  • Adjusted EPS surged 22.9% to $3.65.
  • New drugs offset legacy product revenue decline.
  • Analysts rate Moderate Buy with $272.66 target.

Bearish Signals

  • Humira revenue pressure from waning patent protection.
  • Competition threatens growth in therapeutic areas.
  • Investors scrutinize Juvmo's early commercial outlook.
25
Bullish +65

AbbVie stock nears its record high after a quarterly beat

Earnings report AI-generated analysis

AbbVie Inc. shares approached a record high on September 24, 2026, trading at USD 265.07 after the company reported strong second-quarter financial results. The quarterly earnings per share (EPS) beat analyst consensus estimates by USD 0.04, reaching USD 3.65 against an expected USD 3.61. This...

Bullish Signals

  • Stock at $265.07, just 1.60% below 52-week high of $269.39.